• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond.

作者信息

Huang Huiyao, Miao Huilei, Tang Jinling, Li Ning

机构信息

Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.

Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, Shenzhen, Guangdong, P. R. China.

出版信息

Cancer Commun (Lond). 2025 Jun;45(6):673-676. doi: 10.1002/cac2.70007. Epub 2025 Mar 12.

DOI:10.1002/cac2.70007
PMID:40077834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12187573/
Abstract
摘要

相似文献

1
Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond.对中国及其他地区癌症临床试验限制性入选标准演变的思考与见解。
Cancer Commun (Lond). 2025 Jun;45(6):673-676. doi: 10.1002/cac2.70007. Epub 2025 Mar 12.
2
Transfusion thresholds for guiding red blood cell transfusion.输血阈值指导红细胞输血。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.
3
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.输血阈值及指导异体红细胞输血的其他策略。
Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD002042. doi: 10.1002/14651858.CD002042.pub4.
4
Exclusion of people from oncology clinical trials based on functional status.基于功能状态将患者排除在肿瘤学临床试验之外。
Clin Trials. 2025 Jun;22(3):367-373. doi: 10.1177/17407745241304114. Epub 2025 Jan 2.
5
Interventions to improve antibiotic prescribing practices for hospital inpatients.改善医院住院患者抗生素处方行为的干预措施。
Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.
6
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203).一项以患者为中心、开放标签、多中心的II期研究，评估劳拉替尼单药用于局部晚期或转移性ALK阳性非小细胞肺癌患者一线治疗（CTONG2203）
Clin Lung Cancer. 2025 May 28. doi: 10.1016/j.cllc.2025.05.014.
7
Disclosure to social network members among abortion-seeking women in low- and middle-income countries with restrictive access: a systematic review.寻求堕胎的中低收入国家的妇女向社交网络成员披露信息：系统评价。
Reprod Health. 2021 Jun 7;18(1):114. doi: 10.1186/s12978-021-01165-0.
8
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.对于接受强化化疗或放疗或两者联合治疗、有或没有造血干细胞支持的血液系统恶性肿瘤患者，采用限制性与宽松性红细胞输血策略的比较。
Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD011305. doi: 10.1002/14651858.CD011305.pub2.
9
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.输血阈值及指导异体红细胞输血的其他策略。
Cochrane Database Syst Rev. 2012 Apr 18;4(4):CD002042. doi: 10.1002/14651858.CD002042.pub3.
10
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.成人慢性未抑制的HIV感染中的结构化治疗中断（STI）
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.

本文引用的文献

1
Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data.基于真实世界数据定量评估放宽肺癌药物资格标准对其风险效益比的影响。
Thorac Cancer. 2024 May;15(14):1187-1194. doi: 10.1111/1759-7714.15269. Epub 2024 Apr 4.
2
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.拓宽试验纳入标准对癌症临床试验中纳入脑转移患者的影响：2012-2022 年的时间序列分析。
J Clin Oncol. 2024 Jun 1;42(16):1953-1960. doi: 10.1200/JCO.23.01777. Epub 2024 Mar 27.
3
Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.中国大陆癌症药物临床试验中对老年患者的不公平限制及相应解决方案。
BMC Geriatr. 2023 Mar 30;23(1):199. doi: 10.1186/s12877-023-03886-2.
4
Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.资格标准内容的增长和国家癌症研究所（NCI）附属临床试验的累积失败。
Cancer Med. 2023 Feb;12(4):4715-4724. doi: 10.1002/cam4.5276. Epub 2022 Nov 18.
5
Evaluating eligibility criteria of oncology trials using real-world data and AI.利用真实世界数据和人工智能评估肿瘤学试验的入组标准。
Nature. 2021 Apr;592(7855):629-633. doi: 10.1038/s41586-021-03430-5. Epub 2021 Apr 7.
6
Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice.癌症临床研究的资格：发现、可推广性、惠益和公正的交集。
Clin Cancer Res. 2021 May 1;27(9):2369-2371. doi: 10.1158/1078-0432.CCR-21-0085. Epub 2021 Feb 18.
7
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.阿基仑赛用于复发或难治性大 B 细胞淋巴瘤的标准治疗：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
8
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.重新评估肿瘤学临床试验的资格标准：2015年研究性新药申请分析
J Clin Oncol. 2017 Nov 20;35(33):3745-3752. doi: 10.1200/JCO.2017.73.4186. Epub 2017 Oct 2.
9
Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.胸部肿瘤临床试验的入选标准和要求继续增加数量和复杂性。
J Thorac Oncol. 2017 Oct;12(10):1489-1495. doi: 10.1016/j.jtho.2017.07.020. Epub 2017 Aug 9.
10
External validity of randomised controlled trials: "to whom do the results of this trial apply?".随机对照试验的外部效度：“该试验结果适用于谁？”
Lancet. 2005;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8.